Roche arthritis drug works: FDA staff
WASHINGTON (Reuters) - Roche Holding AG's drug Actemra, known generically as tocilizumab, appears to be effective for treating rheumatoid arthritis, U.S. drug reviewers said in a summary released on Friday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=DoOzUc" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=DoOzUc)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=ZMsuMJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=ZMsuMJ) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=0PCi6j" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=0PCi6j) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=qxvqyj" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=qxvqyj)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/346025542" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/346025542/idUSREE57549420080725